These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12487146)

  • 21. High-throughput high-performance liquid chromatography/mass spectrometry for modern drug discovery.
    Kyranos JN; Cai H; Wei D; Goetzinger WK
    Curr Opin Biotechnol; 2001 Feb; 12(1):105-11. PubMed ID: 11167082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chips to Hits: microarray and microfluidic technologies for high-throughput analysis and drug discovery. September 12-15, 2005, MA, USA.
    Khademhosseini A
    Expert Rev Mol Diagn; 2005 Nov; 5(6):843-6. PubMed ID: 16255625
    [No Abstract]   [Full Text] [Related]  

  • 23. Integrated assessment of preclinical data: shifting high attrition rates to earlier phase drug development.
    Korstanje C
    Curr Opin Investig Drugs; 2003 May; 4(5):519-21. PubMed ID: 12833643
    [No Abstract]   [Full Text] [Related]  

  • 24. Regulatory Forum Opinion Piece
    Morgan SJ; Couch J; Guzzie-Peck P; Keller DA; Kemper R; Otieno MA; Schulingkamp RJ; Jones TW
    Toxicol Pathol; 2017 Apr; 45(3):372-380. PubMed ID: 28351296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic library design.
    Huwe CM
    Drug Discov Today; 2006 Aug; 11(15-16):763-7. PubMed ID: 16846805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical dose number and its application in understanding drug absorption risk and formulation design for preclinical species.
    Wuelfing WP; Daublain P; Kesisoglou F; Templeton A; McGregor C
    Mol Pharm; 2015 Apr; 12(4):1031-9. PubMed ID: 25671350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonclinical development of biopharmaceuticals.
    Baumann A
    Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Process map proposal for the validation of genomic biomarkers.
    Goodsaid F; Frueh F
    Pharmacogenomics; 2006 Jul; 7(5):773-82. PubMed ID: 16886901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GLP: A requirement in cell therapies - perspectives for the cardiovascular field.
    Müller-Ruch U; Skorska A; Lemcke H; Steinhoff G; David R
    Adv Drug Deliv Rev; 2020; 165-166():96-104. PubMed ID: 32305352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of mass spectrometry for in-vitro ADME assays.
    Chu I; Nomeir AA
    Curr Drug Metab; 2006 Jun; 7(5):467-77. PubMed ID: 16787156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Affinity-based screening techniques for enhancing lead discovery.
    Comess KM; Schurdak ME
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):411-6. PubMed ID: 15338950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The emergence and application of technological advances in biotransformation studies.
    Fernandez-Metzler CL; King RC
    Curr Top Med Chem; 2002 Jan; 2(1):67-76. PubMed ID: 11899963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies for success in drug development.
    Wardell WM
    Retina; 2005 Dec; 25(8 Suppl):S100-S102. PubMed ID: 16374309
    [No Abstract]   [Full Text] [Related]  

  • 34. Cytotoxicity tests for high-throughput drug discovery.
    Slater K
    Curr Opin Biotechnol; 2001 Feb; 12(1):70-4. PubMed ID: 11167076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices.
    Valentin JP; Guillon JM; Jenkinson S; Kadambi V; Ravikumar P; Roberts S; Rosenbrier-Ribeiro L; Schmidt F; Armstrong D
    J Pharmacol Toxicol Methods; 2018; 93():7-14. PubMed ID: 30030184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [High throughput screening in the process of drug discovery].
    Ueki T
    Nihon Yakurigaku Zasshi; 2007 Apr; 129(4):276-80. PubMed ID: 17435340
    [No Abstract]   [Full Text] [Related]  

  • 37. [Conducting Assured Nonclinical Studies in the Pharmaceutical Industry: Good Laboratory Practice (GLP) Study, GLP Inspection, and Standards for Assurance].
    Fujikawa Y
    Yakugaku Zasshi; 2019; 139(6):881-885. PubMed ID: 31155530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Commentary: redesigning the preclinical paradigm: the role of pathology and toxicology in supporting discovery research.
    Cockerell GL; Aaron CS; Moe JB
    Toxicol Pathol; 1999; 27(4):477-8. PubMed ID: 10485833
    [No Abstract]   [Full Text] [Related]  

  • 39. Structure-based virtual screening: an overview.
    Lyne PD
    Drug Discov Today; 2002 Oct; 7(20):1047-55. PubMed ID: 12546894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Considerations for conducting imaging studies in support of developmental toxicology studies for regulatory submission.
    Johnson CA; Winkelmann CT; Wise LD
    Reprod Toxicol; 2014 Sep; 48():41-3. PubMed ID: 24863470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.